Rujun Gong

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5411875/publications.pdf

Version: 2024-02-01

		159585	233421
60	2,180	30	45
papers	citations	h-index	g-index

61	61	61	2515
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hepatocyte Growth Factor Ameliorates Renal Interstitial Inflammation in Rat Remnant Kidney by Modulating Tubular Expression of Macrophage Chemoattractant Protein-1 and RANTES. Journal of the American Society of Nephrology: JASN, 2004, 15, 2868-2881.	6.1	99
2	Hepatocyte Growth Factor Suppresses Proinflammatory NFÎºB Activation through GSK3Î² Inactivation in Renal Tubular Epithelial Cells. Journal of Biological Chemistry, 2008, 283, 7401-7410.	3.4	89
3	Hepatocyte Growth Factor Modulates Matrix Metalloproteinases and Plasminogen Activator/Plasmin Proteolytic Pathways in Progressive Renal Interstitial Fibrosis. Journal of the American Society of Nephrology: JASN, 2003, 14, 3047-3060.	6.1	88
4	Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease. Clinical Science, 2019, 133, 1321-1339.	4.3	86
5	The renaissance of corticotropin therapy in proteinuric nephropathies. Nature Reviews Nephrology, 2012, 8, 122-128.	9.6	84
6	Anti-Inflammatory Effect of Hepatocyte Growth Factor in Chronic Kidney Disease: Targeting the Inflamed Vascular Endothelium. Journal of the American Society of Nephrology: JASN, 2006, 17, 2464-2473.	6.1	83
7	Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney International, 2008, 74, 1128-1138.	5.2	74
8	Delayed Administration of a Single Dose of Lithium Promotes Recovery from AKI. Journal of the American Society of Nephrology: JASN, 2014, 25, 488-500.	6.1	74
9	Therapeutic targeting of GSK3Î² enhances the Nrf2 antioxidant response and confers hepatic cytoprotection in hepatitis C. Gut, 2015, 64, 168-179.	12.1	73
10	GSK3Î²-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition. Redox Biology, 2019, 26, 101275.	9.0	69
11	Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3Î² Reinforces the Nrf2 Antioxidant Defense against Podocytopathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 2289-2308.	6.1	68
12	The ageing kidney: Molecular mechanisms and clinical implications. Ageing Research Reviews, 2020, 63, 101151.	10.9	64
13	Inhibition of glycogen synthase kinase-3Î² prevents NSAID-induced acute kidney injury. Kidney International, 2012, 81, 662-673.	5.2	63
14	What we need to know about the effect of lithium on the kidney. American Journal of Physiology - Renal Physiology, 2016, 311, F1168-F1171.	2.7	56
15	The ketone body Î²-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults. Kidney International, 2021, 100, 1037-1053.	5.2	51
16	Glycogen Synthase Kinase 3Î² Dictates Podocyte Motility and Focal Adhesion Turnover by Modulating Paxillin Activity. American Journal of Pathology, 2014, 184, 2742-2756.	3.8	50
17	Leveraging Melanocortin Pathways to Treat Glomerular Diseases. Advances in Chronic Kidney Disease, 2014, 21, 134-151.	1.4	49
18	Blocking Macrophage Migration Inhibitory Factor Protects Against Cisplatin-Induced Acute Kidney Injury in Mice. Molecular Therapy, 2018, 26, 2523-2532.	8.2	49

#	Article	IF	Citations
19	Redox-sensitive glycogen synthase kinase 3Î²-directed control of mitochondrial permeability transition: rheostatic regulation of acute kidney injury. Free Radical Biology and Medicine, 2013, 65, 849-858.	2.9	48
20	Fine-tuning of NFÎºB by glycogen synthase kinase 3Î² directs the fate of glomerular podocytes upon injury. Kidney International, 2015, 87, 1176-1190.	5.2	47
21	The Î² isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy. Journal of Pathology, 2016, 239, 23-35.	4.5	42
22	Activation of FXR protects against renal fibrosis via suppressing Smad3 expression. Scientific Reports, 2016, 6, 37234.	3.3	40
23	Pharmacological targeting of <scp>GSK3Î²</scp> confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition. British Journal of Pharmacology, 2015, 172, 895-909.	5.4	38
24	Melanocortin 5 receptor signaling pathway in health and disease. Cellular and Molecular Life Sciences, 2020, 77, 3831-3840.	5.4	38
25	Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney International, 2013, 83, 635-646.	5.2	36
26	Glycogen synthase kinase 3Î² hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease. Kidney International, 2020, 97, 175-192.	5.2	36
27	Age-related GSK3Î² overexpression drives podocyte senescence and glomerular aging. Journal of Clinical Investigation, 2022, 132, .	8.2	36
28	Activation of PI3Kâ€“Aktâ€“GSK3Î² pathway mediates hepatocyte growth factor inhibition of RANTES expression in renal tubular epithelial cells. Biochemical and Biophysical Research Communications, 2005, 330, 27-33.	2.1	35
29	Lithium targeting of AMPK protects against cisplatinâ€induced acute kidney injury by enhancing autophagy in renal proximal tubular epithelial cells. FASEB Journal, 2019, 33, 14370-14381.	0.5	35
30	Glycogen Synthase Kinase 3Î² Orchestrates Microtubule Remodeling in Compensatory Glomerular Adaptation to Podocyte Depletion. Journal of Biological Chemistry, 2015, 290, 1348-1363.	3.4	34
31	Rescue therapy with Tanshinone IIA hinders transition of acute kidney injury to chronic kidney disease via targeting GSK3Î². Scientific Reports, 2016, 6, 36698.	3.3	34
32	Tanshinone IIA Attenuates Renal Fibrosis after Acute Kidney Injury in a Mouse Model through Inhibition of Fibrocytes Recruitment. BioMed Research International, 2015, 2015, 1-10.	1.9	31
33	Remote Ischemic Preconditioning for Kidney Protection: GSK3Î²-Centric Insights Into the Mechanism of Action. American Journal of Kidney Diseases, 2015, 66, 846-856.	1.9	31
34	Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease. Clinical Science, 2015, 128, 527-535.	4.3	26
35	Human renal 11Î²-hydroxysteroid dehydrogenase 1 functions and co-localizes with COX-2. Life Sciences, 2008, 82, 631-637.	4.3	25
36	Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease. Frontiers in Endocrinology, 2021, 12, 749010.	3.5	24

#	Article	IF	Citations
37	Multi-target anti-inflammatory action of hepatocyte growth factor. Current Opinion in Investigational Drugs, 2008, 9, 1163-70.	2.3	24
38	Conditional ablation of glycogen synthase kinase 3Î² in postnatal mouse kidney. Laboratory Investigation, 2011, 91, 85-96.	3.7	21
39	RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease. Cell Death and Disease, 2020, 11, 413.	6.3	21
40	The redox sensitive glycogen synthase kinase 3Î² suppresses the self-protective antioxidant response in podocytes upon oxidative glomerular injury. Oncotarget, 2015, 6, 39493-39506.	1.8	21
41	Variable expression of 11Î² Hydroxysteroid dehydrogenase (11Î²-HSD) isoforms in vascular endothelial cells. Steroids, 2008, 73, 1187-1196.	1.8	20
42	MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy. Scientific Reports, 2016, 6, 27589.	3.3	20
43	Transglutaminase-1 Regulates Renal Epithelial Cell Proliferation through Activation of Stat-3. Journal of Biological Chemistry, 2009, 284, 3345-3353.	3.4	17
44	Microdose Lithium Protects against Pancreatic Islet Destruction and Renal Impairment in Streptozotocin-Elicited Diabetes. Antioxidants, 2021, 10, 138.	5.1	16
45	Permissive effect of GSK3Î² on profibrogenic plasticity of renal tubular cells in progressive chronic kidney disease. Cell Death and Disease, 2021, 12, 432.	6.3	15
46	Targeting Regulatory T Cells for Transplant Tolerance: New Insights and Future Perspectives. Kidney Diseases (Basel, Switzerland), 2018, 4, 205-213.	2.5	13
47	Mineralocorticoid receptor: A hidden culprit for hemodialysis vascular access dysfunction. EBioMedicine, 2019, 39, 621-627.	6.1	10
48	Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling. Clinical Science, 2020, 134, 695-710.	4.3	10
49	Co-localization of glucocorticoid metabolizing and prostaglandin synthesizing enzymes in rat kidney and liver. Life Sciences, 2008, 83, 725-731.	4.3	9
50	Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in Physiology, 2021, 12, 651236.	2.8	9
51	Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure due to Chronic Cardiorenal Syndrome. BioMed Research International, 2018, 2018, 1-9.	1.9	8
52	Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody. Pediatrics, 2017, 140, e20162169.	2.1	7
53	Ecdysone Elicits Chronic Renal Impairment via Mineralocorticoid-Like Pathogenic Activities. Cellular Physiology and Biochemistry, 2018, 49, 1633-1645.	1.6	6
54	Activation of mineralocorticoid receptor by ecdysone, an adaptogenic and anabolic ecdysteroid, promotes glomerular injury and proteinuria involving overactive GSK3Î² pathway signaling. Scientific Reports, 2018, 8, 12225.	3.3	6

#	Article	IF	Citations
55	Valproate hampers podocyte acquisition of immune phenotypes via intercepting the GSK3Î² facilitated NFκB activation. Oncotarget, 2017, 8, 88332-88344.	1.8	6
56	Rationale and Design of Assessing the Effectiveness of Short-Term Low-Dose Lithium Therapy in Averting Cardiac Surgery-Associated Acute Kidney Injury: A Randomized, Double Blinded, Placebo Controlled Pilot Trial. Frontiers in Medicine, 2021, 8, 639402.	2.6	5
57	Relapse of Nephrotic Syndrome after Adrenocorticotropic Hormone-Induced Remission: Implications of Adrenocorticotropic Hormone Antibodies. American Journal of Nephrology, 2020, 51, 390-394.	3.1	4
58	Triptolide potentiates the cytoskeleton-stabilizing activity of cyclosporine A in glomerular podocytes a GSK3Î² dependent mechanism. American Journal of Translational Research (discontinued), 2020, 12, 800-812.	0.0	4
59	Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats With Puromycin Aminonucleoside Nephrosis. Frontiers in Physiology, 2022, 13, .	2.8	2
60	The Janus view: Dual roles for hypoxia-inducible factor in renal repair after acute kidney injury. American Journal of Physiology - Renal Physiology, 0, , .	2.7	1